

RECEIVED
CENTRAL FAX CENTER

AUG 23 2005

FACSIMILE COVER SHEET

Licata & Tyrrell P.C.

66 E. Main Street
Marlton, New Jersey

Tel: (856) 810-1515
Fax: (856) 810-1454

August 23, 2005

TO: Examiner Yaen

GROUP: 1642

FAX NUMBER: 571-273-8300

ATTORNEY DOCKET NO.: MCP-0141

SERIAL NO.: 09/744,406

FILED: January 22, 2001

NUMBER OF PAGE:

MESSAGE: Attached please find Amendment Transmittal Letter; Reply to the Office Action mailed June 3, 2005; and Certificate of Transmission by Facsimile.


Kathleen A. Tyrrell, Registration No. 38,350


**URGENT! PLEASE DELIVER IMMEDIATELY
UPON RECEIPT. THANK YOU!**

If you have any questions, or did not receive the proper number of pages, or had trouble during transmission, please call 856-810-1515.

CONFIDENTIALITY NOTICE

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying, distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8) Applicant(s): Halpern and England			Docket No. MCP-0141
Application No. 09/744,406	Filing Date January 22, 2001	Examiner Yaen, Christopher H.	Group Art Unit 1642
Invention: Allogeneic Cellular Immunogens Useful as Cancer Vaccines			RECEIVED CENTRAL FAX CENTER AUG 23 2005
I hereby certify that this <u>Reply under 37 CFR 1.116</u> (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>571-273-8300</u>) on <u>August 23, 2005</u> (Date)			
<div style="text-align: right;"><u>Kathleen A. Tyrrell</u> (Typed or Printed Name of Person Signing Certificate)  (Signature)</div>			
Note: Each paper must have its own certificate of mailing.			

AMENDMENT TRANSMITTAL LETTER (Small Entity)				Docket No. MCP-0141	
Applicant(s): Halpern and England					
Application No. 09/744,406	Filing Date January 2001	Examiner Yaen, Christopher H.	Customer No. 26259	Group Art Unit 1642	Confirmation No. 5749
Invention: Allogeneic Cellular Immunogens Useful as Cancer Vaccines					
COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	4 -	20 =	0	x \$25.00	\$0.00
INDEP. CLAIMS	4 -	4 =	0	x \$100.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____					
<input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619					
<input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.					
<input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
<div style="text-align: center;"> _____ Signature Kathleen A. Tyrrell, Reg. No. 38,350</div>			Dated: August 23, 2005		
cc:			<div>I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ (Date)</div> <div>_____ Signature of Person Mailing Correspondence</div> <div>_____ Typed or Printed Name of Person Mailing Correspondence</div>		

RECEIVED
CENTRAL FAX CENTER

AUG 23 2005

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1642


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 7933-38 (MCP-0141)
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Examiner: Yaen, Christopher H.
Group Art Unit: 1642
Title: Allogeneic Cellular Immunogens
Useful as Cancer Vaccines

Certificate of Facsimile Transmission

I hereby certify that this document is being facsimile
transmitted to the Patent and Trademark Office on
the date shown below.

On August 23, 2005


Kathleen A. Tyrrell, Registration No. 38,350

Mail Stop
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

AMENDMENT UNDER 37 C.F.R. 1.116

This reply is being filed in response to the Final
Rejection mailed June 3, 2005 setting a three month
statutory period for response. Please enter the following
amendment and remarks into the record.

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Page 2

Amendments to the claims are reflected in the listing
of claims which begins on page 3 of this paper.

Remarks begin on page 7.